A phase 1b study of the safety, pharmacokinetics, and preliminary antitumor activity of citarinostat (ACY-241) in combination with paclitaxel (Pac) in patients (pts) with advanced solid tumors (AST).

Michael S. Gordon,Geoffrey I. Shapiro,John Sarantopoulos,Dejan Juric,Brian Lu,Peng Chen,Jamie N. Connarn,Yvan Le Bruchec,R. Donald Harvey

A phase 1b study of the safety, pharmacokinetics, and preliminary antitumor activity of citarinostat (ACY-241) in combination with paclitaxel (Pac) in patients (pts) with advanced solid tumors (AST).

2018

Michael S. Gordon
Geoffrey I. Shapiro
John Sarantopoulos
Dejan Juric
Brian Lu
Peng Chen
Jamie N. Connarn
Yvan Le Bruchec
R. Donald Harvey

2547Background: Citarinostat is an oral, selective histone deacetylase 6 inhibitor that inhibits growth of solid tumor cell lines and exhibits potent synergy with Pac in preclinical studies. We con...

Keywords:

Cancer research
Paclitaxel
Pathology
Medicine
Pharmacokinetics
antitumor activity
in patient
solid tumor
HDAC6
Cell culture

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations